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Abstract 
Purpose: This review examines generic preference based measures and their ability to 
reflect health related quality of life in patients with visual disorders. 
Methods: A systematic search was undertaken to identify clinical studies of patients with 
visual disorders where health state utility values (HSUVs) were measured and reported. 
Data were extracted to assess the validity and responsiveness of the measures. A narrative 
synthesis of the data was undertaken due to the heterogeneity between different studies. 
Results: There was considerable heterogeneity in the 31 studies identified in terms of 
patient characteristics, visual disorders and outcomes reported. Vision loss was associated 
with a reduction in scores across the preference-based measure, but the evidence on 
validity and responsiveness was mixed.  The EQ-5D’s performance differed according to 
condition, with poor performance in age-related macular degeneration and diabetic 
retinopathy. The more limited evidence on the HUI-3 found it performed best in 
differentiating between severity groups of patients with glaucoma, AMD, cataracts and 
diabetic retinopathy. One study reported data on the SF-6D and showed it was able to 
differentiate between patients with AMD. 
Conclusion: The performance of the EQ-5D in visual disorders was mixed. The HUI-3 seemed 
to perform better in some conditions, but the evidence on this and SF-6D is limited. More 
head to head comparisons of these three measures are required. The new 5-level version of 
EQ-5D may do better at the milder end of visual function and there is research being 
undertaken into adding a vision relevant dimension.    
Keywords 
Vision, Health-related Quality of Life, Quality of Life, QALYs, Utilities 
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Abbreviations 
AMD – Age-Related Macular Degeneration 
CS – Contrast Sensitivity 
HADS – Hospital Anxiety and Depression Scale 
HRQoL – Health-related Quality of Life 
HSUV – Health State Utility Value 
IDEEI – Impact of Dry Eyes on Everyday Life questionnaire 
HUI-3 – Health Utilities Index Mark 3 
NICE – National Institute for Health and Clinical Excellence 
NV-AMD – Neovascular Age-Related Macular Degeneration 
PL – Perception of Light 
QALY – Quality Adjusted Life Year 
RQKQ – Rhinconjunctivitis Quality of Life Questionnaire 
SF-6D – Short Form Six Dimension 
SG – Standard Gamble 
TTO – Time Trade Off 
VA – Visual Acuity 
VAS – Visual Analogue Scale 
VF-4D – Visual Function instrument (4 dimension) 
VF-14 – Visual Function instrument (14 item version) 
VFA – Visual Function Assessment 
VFQ-25 – Visual Function Questionnaire (25 Item version) 
 
4 
 
Introduction 
Health state utility values (HSUVs) (Torrance, 1986) are key parameters for economic 
evaluations that use a cost-utility analysis framework. Cost-utility analyses return a cost 
effectiveness estimate for a new intervention in terms of the incremental cost per quality 
adjusted life year (QALY) gained. Reimbursement agencies such as the National Institute for 
Health and Clinical Excellence (NICE) in the UK, as well as other similar organisations 
worldwide, routinely undertake cost-utility analyses for new health care interventions. 
HSUVs are most frequently derived from a description of a health state by a patient using a 
standardised generic instrument such as the EQ-5D, the SF-6D or the HUI-3. The patient’s 
description is valued using a set of values obtained for each possible health state taken from 
a general population sample. These values are elicited using standard health state valuation 
techniques such as visual analogue scaling (VAS), standard gamble (SG) or time trade off 
(TTO). 
It has been shown that the different instruments for obtaining HSUVs produce different 
values (Longworth & Bryan, 2003; Brazier, Roberts, Tsuchiya, & Busschbach, 2004; O'brien 
et al., 2003). It is important to assess the validity of any health outcome instrument, 
including those used to obtain HSUVs, in the particular condition of interest. Three widely 
used measures are EQ-5D, SF-6D and HUI-3. EQ-5D is a five dimension instrument, and 
measures the impact of a health state on mobility, self-care, usual activities, 
pain/discomfort, and depression/anxiety. Each dimension is given one of three levels of 
severity, which results in 243 unique health states (though a 5 level version of the 
descriptive system has recently been developed). The SF-6D (a classification system for the 
SF-36 and SF-12 health questionnaires) has six dimensions and either four or six severity 
levels. This results in 18,000 possible unique health states. The HUI-3 has eight dimensions 
and either five or six severity levels, resulting in 972,000 possible unique health states. The 
additional dimensions and levels may increase the instruments responsiveness to particular 
changes in health status; however this comes at the cost of increased patient burden and 
completion time, as well as requiring more health state valuations and/or increased 
uncertainty around these values. These instruments differ in the dimensions described, the 
number of levels and the severity range covered which may have implications for the 
appropriateness of an instrument to describe particular conditions. The fewer dimensions 
and levels in the EQ-5D compared to other instruments has been seen by some as a 
limitation. However the EQ-5D has been validated in many clinical areas and has shown that 
it has construct validity and is responsive to change (Brazier et al., 2004). 
There has been concern over the validity of the EQ-5D instrument (Brazier et al., 2004; 
Browne et al., 2007) and SF-6D (Browne et al., 2007) in some visual disorders. Visual 
disorders are a broad set of conditions that can affect a patient in a range of ways. Certain 
conditions are painful, can affect central or peripheral vision, can affect one or both eyes 
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and can therefore impact on a patient’s HRQoL. The aim of this review is to examine the 
appropriateness of the EQ-5D, SF-6D and HUI-3 in patients within visual disorders due to the 
different ways particular conditions impact on HRQoL.  
 
Methods 
Search strategy and data identification 
The objective of the literature review was to identify relevant journal papers reporting 
evidence of the performance of EQ-5D, SF-6D and HUI-3 in patients with visual disorders. 
A broad search was conducted to identify studies reporting preference-based utility 
instruments that were used to examine the HRQoL of patients with a visual disorder. BIOSIS, 
CINAHL, EMBASE, MEDLINE, PsychINFO, Web of Science electronic databases and the 
Euroqol website were searched. A search strategy was developed following consultation 
with experts in information resources and health economics. The search included both free 
text and controlled terms. Free text words included ‘visual disorder’, ‘euroqol’, ‘hui3’, ‘sf6d’ 
(all with alternative spellings). Specific visual disorders were also searched, including 
‘cataracts’, ‘retinopathy’ and ‘macular degeneration’. The criteria for inclusion was that 
patients had a visual disorder, the study reported at least one from the EQ-5D, SF-6D or HUI-
3 and reported another measure of quality of life (generic or condition-specific) or a 
measure of clinical severity. Papers that used vignettes or own health state valuations were 
excluded. There was no restriction relating to the type of study. Due to resource limitations 
only English language studies were reviewed. 
 
Analytic strategy 
Data Extraction 
Data were extracted from the studies using a standardised set of forms developed for this 
study after reviewing forms used for similar studies in other disease areas (Papaioannou, 
Brazier, & Parry, 2010; Pickard, Wilke, Lin, & Lloyd, 2007). Data extracted included:  
• Study Characteristics – Country, type of visual disorder, disease or treatment stage, 
any treatment given, study type 
• Participant Characteristics – Number of participants, age, gender, ethnicity, 
proportion of missing data 
• Instrument used – EQ-5D/SF-6D/HUI-3, other health-related utility measures, other 
generic measures of HRQoL, condition specific HRQoL measures and clinical 
measures of disease severity,  
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• Health state utility values – index mean, scoring algorithm, VAS mean 
• Construct and convergent validity  
• Responsiveness  
 
Assessment of quality 
The assessment of quality of included studies requires a different methodology from the 
conventional approach required for reviewing clinical evidence. Of most importance was the 
relevance of the study in terms of the patient population. For studies that included a mixed 
population of patients (i.e. with various chronic conditions), then studies were only included 
if they reported HSUV’s for sub-groups of patients with a specific visual disorder. 
Also important are response or completion rates, which may have some implications for 
generalisability and provide evidence on the acceptability of the questionnaire to patients.  
 
Assessment of validity 
Validity is defined as how well an instrument measures what it was intended to measure. 
More specifically, for instruments constructed to measure HRQoL, whether the dimensions 
adequately cover the key determinants of HRQoL. Criterion validity would be determined by 
comparing an instrument to an established gold-standard. However a gold-standard for 
measuring health-related utility has not been established. Therefore researchers seek 
evidence that supports or otherwise the validity of a measure using the idea of construct 
validity, which attempts to see if patterns in scores confirm prior constructs. 
The most common test to identify construct validity is the ‘known group’ method. This 
compares the results of a preference based measure between groups of patients that are 
expected to differ in the construct. If a study presents a population stratified on the basis of 
a clinical indicator, then one can investigate the ability of a preference based measure to 
distinguish between these groups. It should be noted that the usefulness of these 
comparisons can be limited by sample size (especially as studies are usually not powered on 
a preference based measure), the appropriateness of the clinical groups defined, and 
exogenous factors that may influence quality of life. For instance, groups defined solely by 
the presence of a biomarker will not have a clinical difference that impacts on their HRQoL. 
Also, if patients have a number of co-morbidities then these may have a greater impact on 
HRQoL than the condition of interest. Known groups can be defined using a case-control 
analysis. However, a more stringent test is to define known groups based on different levels 
of condition severity. 
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A sub-set of construct validity is known as convergent validity. This is defined as the extent 
to which one measure correlates with another measure of the same concept. In this review, 
this would be the extent to which EQ-5D, SF-6D or the HUI-3 correlate with each other and 
with measures of vision problems or quality of life. 
 
Assessment of reliability 
The reliability of a measure is defined as its ability to reproduce results when measurements 
are repeated on an unchanged population (Brazier & Deverill, 1999). Reliability can be 
measured by re-testing and reporting either the correlation or difference between 
estimates.   
 
Assessment of responsiveness 
Responsiveness is the ability to measure a change in health status. A pre/post intervention 
study which reports EQ-5D, SF-6D or the HUI-3 and another valid measure of health change 
would allow the responsiveness of a measure due to change in health status to be 
identified. As with the tests of validity, it is important to consider whether the measures of 
health change that are being used for comparison are themselves valid. In addition, it is 
important to consider whether other health changes not directly related to the condition 
could have impacted upon health-related utility (for example, side effects of treatment).  
 
Presentation and analysis 
Tables presenting summaries of the study characteristics, analyses on the impact of visual 
acuity on HSUVs are presented. The analysis will be broken down into particular visual 
disorders to allow for conclusions to be formed both on specific disorders as well as visual 
disorders as a whole. Heterogeneity in the studies reviewed, in terms of study design and 
patient populations, means that a formal meta-analysis would be inappropriate. 
 
Results 
Search results 
Bibliographic searching was completed in August 2010. A total of 1,025 potentially relevant 
papers were identified. Abstracts and titles for all papers were screened to identify papers 
meeting the inclusion criteria. 969 records were excluded, and full papers were ordered for 
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the remaining 56 records. After reviewing the full papers, 25 were excluded and a total of 31 
papers were included in the review.  A flow chart of the study selection process is shown in 
Figure 1. 
 ((INSERT FIGURE 1 HERE)) 
The 31 studies identified from the bibliographic search are presented in Table 1 and 2. Thirty 
of the 31 studies were observational studies, with the remaining study being a randomised 
controlled trial. The selected studies were conducted in different countries; three are multi-
country studies, three are in the US, five in Canada and nine are from the UK. 
((INSERT TABLE 1 HERE)) 
((INSERT TABLE 2 HERE)) 
 
Quality of Studies 
A judgement regarding the risk of bias of each study was determined by reviewing the 
methods of patient recruitment, and noting any missing data reported (either study drop-
outs or incomplete questionnaires). A range of recruitment procedures was seen in the 
review, and this was usually determined by the study design. Some involved a retrospective 
analysis of datasets (Mittmann, Chan, Trakas, & Risebrough, 2001; Asakawa et al., 2008) 
with a pre-determined inclusion criteria, a number of studies were either case-controlled 
analyses (Polack et al., 2010; Polack et al., 2008; Polack et al., 2007), but the majority were 
cross-sectional observational studies. The RCT reviewed (Datta et al., 2008) had well defined 
inclusion criteria. As is typical, in the longitudinal studies some patients dropped out before 
the end of the study. The general implication of patients dropping out was that no 
measurements were taken. Response rates for questionnaires range from 33% to 96%, with 
completion rates of longitudinal studies above 85% in all but one study (range 52% to 
98.1%). 
 
Patient Characteristics 
The studies identified were in a wide range of visual disorders. Nine studies were in patients 
with cataract (Jayamanne et al., 1999; Polack et al., 2007; Polack et al., 2008; Black et al., 
2009; Asakawa et al., 2008; Datta et al., 2008; Polack et al., 2010; Conner-Spady et al., 
2005). Seven studies were in patients with age related macular degeneration (AMD) 
(Espallargues et al., 2005; Lotery et al., 2007; Soubrane et al., 2007; Ruiz-Moreno et al., 
2008; Cruess et al., 2007; Payakachat et al., 2009; Kim et al., 2010), 5 studies were in 
patients with glaucoma (Aspinall et al., 2008; Kobelt et al., 2006; Mittmann et al., 2001; 
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Thygesen et al., 2008; Montemayor et al., 2001). Three studies were in patients with 
conjunctivitis (Smith et al., 2005; Pitt et al., 2004; Rajagopalan et al., 2005), 2 studies were in 
patients with diabetic retinopathy (Smith et al., 2008; Lloyd et al., 2008) and the remaining 6 
studies were in populations with various other visual conditions. 
The inclusion criteria varied across the studies reviewed within each of the specific 
conditions. This was due to the study design, the study methodology and also in some 
studies the inclusion criteria was unclear. Some studies reported that patients were 
identified through case notes, but no more details are provided. It was noted whether AMD 
was bilateral or unilateral and wet or dry, whether cataracts were first or second eye, and 
whether glaucoma was primary or multiple. 
 
Reliability 
No tests of reliability were performed on the generic preference based measures. 
 
Construct validity 
Twenty-one of the 31 studies allow a known group analysis to be performed, 17 for the EQ-
5D, 4 for the HUI-3 but no studies for the SF-6D. In 6 of the studies, groups were defined by 
visual acuity (VA), or by contrast sensitivity (CS). These were clearly defined groups with 
mean estimates of utility provided for each group (Langelaan et al., 2007; Lloyd et al., 2008; 
Smith et al., 2005; Soubrane et al., 2007; Thygesen et al., 2008; Espallargues et al., 2005). 
The remaining 25 studies had either a case-control design, had differing conditions, or did 
not define levels of severity. 
The differences in clinical definition of groups, conditions, characteristics of patients, and 
study designs do not allow for a direct comparison of the utility values, or a meta-analysis.  
((INSERT TABLE 3 HERE)) 
 
Convergent validity  
Nine of the 31 studies reviewed provide evidence on correlation or regression between 
generic measure of HRQoL with either each other or with visual measures. Eight studies 
report evidence of convergent validity in the EQ-5D compared to a visual measure, with 
Espallargues et al. also reporting correlations across EQ-5D, SF-6D and HUI-3.  
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Glaucoma 
Construct Validity 
Three studies of the EQ-5D allowed an analysis of groups defined by severity of vision 
problems in glaucoma patients (see Table 3). Aspinall et al. present EQ-5D utility values 
stratified by mild, moderate and severe visual field loss. The values decrease appropriately 
but are not statistically significant. Kobelt et al. saw the EQ-5D decrease with increasing 
glaucomatous damage, but the difference between groups was not statistically significant 
when controlling for co-morbidity, except for the most severe group. The study by Thygesen 
et al. defined three groups on the basis of the Snellen score, and saw consistent ordering of 
mean utility values.  
No such data were available for HUI-3 or SF-6D. However, one paper reported the use of 
HUI-3 in a case-control study, which showed a significant and appropriate difference in HUI-
3 between cases and controls (Mittmann et al., 2001). 
 
Convergent Validity 
Three studies report correlation statistics for EQ-5D with VA in patients with glaucoma 
(Aspinall et al., 2008; Montemayor et al., 2001; Thygesen et al., 2008). Aspinall et al. found 
moderate and statistically significant correlations for the mobility, self-care and anxiety 
dimensions, along with the summed index score. However Montemayor et al. did not find 
significant correlations for EQ-5D with VA. The study by Thygesen et al. showed a significant 
correlation between VA and EQ-5D. 
 
Responsiveness 
No studies reported responsiveness in patients with glaucoma. 
 
AMD 
Construct Validity 
Of the seven papers, six allowed an assessment of construct validity of the EQ-5D in people 
with AMD. Of these, three differentiated between groups based on severity of vision 
disorder and four included assessments of cases against controls (one of which also grouped 
by severity).   
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Of the case-control studies, three found that EQ-5D showed an appropriate and statistically 
significant reduction in HRQoL for people with AMD compared to general population 
controls (Lotery et al., 2007; Ruiz-Moreno et al., 2008; Soubrane et al., 2007). One reported 
a difference that was not statistically significant difference, but the difference was in the 
appropriate direction (Cruess et al., 2007). 
Three studies differentiated in terms of severity: one in terms of levels of visual acuity and 
the other based on whether they had unilateral or bilateral AMD. Soubrane et al. showed 
inconsistency with the mean estimates, with normal VA (>20/40) having a worse mean 
utility (0.69) when compared to mild, moderate, severe and near blind utility values. This 
inconsistency was not seen in the VFQ-25, however the HADS anxiety dimension was also 
inconsistent between the normal and mild VA groups. The study did however show a 
significant difference between those with NV-AMD and the control group. The study was 
relatively large (N=401 NV-AMD patients) however proportions in each group are not 
provided. Kim et al. found a statistically significant difference in EQ-5D values between 
those with unilateral and bilateral AMD. Espallargues et al. found a consistent relationship 
between VA and CS with HUI-3, SF-6D, TTO and VAS but not the EQ-5D. 
 
Convergent Validity 
Only Espallergues et al. provided correlation statistics between generic and visual measures 
in patients with AMD. They found that the VAS, TTO, HUI-3 and SF-6D were all significantly 
correlated with both VA and CS. However they did not find significant correlations for EQ-5D 
with VA or CS. 
 
Responsiveness 
Kim et al. reported a statistically significant improvement in both the VF-4D and the EQ-5D 
after photodynamic therapy in patients with AMD.  
 
Cataracts 
Construct Validity 
Five of the 7 studies in people with cataracts allowed an assessment of the construct validity 
of the EQ-5D. Conner-Spady et al. identified an appropriate but non-significant change in 
EQ-5D between first and second eye surgery groups. Three case-control studies conducted 
in different countries by Polack et al (2007,2008 and 2010) found that there were significant 
differences in EQ-5D between cases and controls, and found that cases were likely to report 
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a significant difference across all dimensions (except pain dimension in Polack et al. 2008). 
However, there was no strong evidence to support a significant and consistent association 
between the degree of VA and EQ-5D. Polack et al. 2010 reports an inconsistent association 
between EQ-5D and VA level. 
One study reports HUI-3 values for cases and control (Asakawa et al., 2008), and identifies 
statistically significant and appropriate difference between the two groups. 
 
Convergent Validity 
Three studies provide evidence of the convergent validity of the EQ-5D with VA. Polack et al. 
2007 and 2008 tested associations between EQ-5D and VA, with one finding that poorer VA 
was associated with higher odds of reporting any problem with all EQ-5D dimensions apart 
from anxiety (Polack et al., 2007). The other study found no significant associations between 
VA and EQ-5D dimensions, apart from a borderline association with self-care (p=0.05) 
(Polack et al., 2008). Datta et al. did not find significant correlations for EQ-5D with VA. 
 
Responsiveness 
Black et al. reported a statistically significant improvement in both the VF-14 and the EQ-5D 
post cataract surgery, though the later was relatively small. Conner-Spady et al. reported a 
statistically significant improvement in the VFA and VA post cataract surgery, but the 
subsequent mean improvements in EQ-VAS and EQ-5D were small and not statistically 
significant. This may suggest that the EQ-5D is not responsive in this population, however it 
should be recognised that the study was not initially powered to identify statistically 
significant changes, and a mean improvement was identified. Also the VAS did not change 
pre-post treatment, so it could be that the treatment did not significantly impact on HRQoL. 
 
Diabetic Retinopathy 
Construct Validity 
Two studies reported the EQ-5D identifying a statistically significant difference between the 
two extreme groups, however the differences between neighbouring groups were not 
significant, and frequently inconsistent (Smith et al., 2008; Lloyd et al., 2008). In the study by 
Lloyd et al, the inconsistencies were also shown in VAS ratings of patients’ own health and 
the HUI-3. This may be due to small sample sizes or the authors speculate whether it may be 
due to a loss of independence of the participants when they reach that level of severity.  
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Convergent Validity 
Smith et al. fitted a linear regression and found visual angle to be a predictor of EQ-5D utility 
values. They also fitted a non-parametric ordinal logistic regression and this estimated that 
any degree of visual impairment would see an increased likelihood of reporting non-perfect 
utility values. 
 
Responsiveness 
No papers reported the responsiveness of the measures in patients with diabetic 
retinopathy. 
 
Conjunctivitis 
Construct Validity 
All three studies allowed an assessment of construct validity of the EQ-5D in people with 
conjunctivitis. All three were case-control studies and showed a statistically significant 
difference between cases and controls (Rajagopalan et al., 2005; Pitt et al., 2004; Smith et 
al., 2005). Within the dimensions of the EQ-5D, The study by Pitt et al. found the pain 
dimension to be the only dimension to show a statistical difference. The Smith et al. study 
saw a significant difference across all dimensions except mobility. No studies provide 
evidence on the construct validity of the HUI-3 or SF-6D. 
 
Convergent Validity and responsiveness 
No papers reported on convergent validity or the responsiveness of the measures in 
patients with conjunctivitis. 
 
Other Visual Conditions 
Construct Validity 
The remaining five studies were in unique visual conditions. Three of these studies allow an 
assessment of the construct validity of the EQ-5D, and two of the HUI-3.  
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Clark et al. and Kempen et al. reported an appropriate but non-significant difference in the 
EQ-5D between the control group and those with endophthalmitis and cytomegalovirus, 
respectively. Langelaan et al. undertook a study in visually impaired patients, and identified 
an appropriate but non-significant difference in the EQ-5D between low and high visual field 
groups, but an inconsistent and non-significant difference in the EQ-5D between low and 
high visual acuity groups. 
Boulton et al. and Quinn et al. found the HUI-3 identified statistically significant and 
appropriate differences between groups of patients with unspecified blindness/visual 
impairment.  
 
Convergent Validity 
van Nispen et al. undertook a multivariate regression analysis in older patients with a visual 
impairment. They found that worsening VA was a significant risk factor for a lower EQ-5D 
value. 
 
Responsiveness 
None of the papers reported data on the responsiveness of the measures. 
 
Discussion 
The 31 studies found in this review show a worsening of utility values as visual impairment 
increases in many though not all studies. The magnitude and statistical significance of the 
association varied between different generic preference-based measures of health related 
quality of life.  
The largest amount of evidence was found for the EQ-5D compared to the other generic 
measures and the results were mixed. Nearly all studies showed significant differences 
between patients with the condition and a control group without it. However, this is a very 
crude test of construct validity and furthermore, many were not well controlled for age and 
other conditions then their conclusions may be limited.  Studies comparing EQ-5D scores 
across severity groups were more mixed, with most showing little or no difference between 
groups defined by clinical measures of visual impairment.  There was limited evidence on 
responsiveness, only in the form of before and after an intervention.  The few studies 
identified changes consistent with an effective intervention, but differences were 
statistically significant in only two of three studies. The assessment of convergent validity 
was more concerning, with several studies not demonstrating a statistically significant 
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correlation with clinical measures. Whilst there was less evidence for the HUI-3, all but one 
study demonstrated good validity; no studies assessed responsiveness. There was very 
limited evidence on the SF-6D in patients with visual impairment. 
((INSERT TABLE 4 HERE)) 
The results can also be grouped by visual disorder so to examine the performance of each 
generic measure. A summary of the overall performance by visual disorder is provided in 
Table 4. The EQ-5D performs well in patients with conjunctivitis, however the evidence is 
limited to case-control studies and no comparison is made to either generic HRQoL or 
clinical measures. In patients with diabetic retinopathy, both the EQ-5D and the HUI-3 
distinguished between patients with and without the condition, however some evidence 
showed that both instruments were unable to distinguish between severity levels The EQ-
5D was found to correlate with clinical measures in patients with diabetic retinopathy. In 
patients with AMD, the EQ-5D distinguished between patients with and without the 
condition, however it was unable to distinguish between severity levels and did not 
correlate well with other measures. The HUI-3 and the SF-6D did however distinguish 
according to severity and correlated well with other measures.  Case-control evidence 
supports the EQ-5D and HUI-3 in patients with cataracts. One study of the EQ-5D in people 
with cataracts showed a non-significant trend reflecting severity, however the association of 
EQ-5D dimensions with other measures of severity was mixed.  
In patients with glaucoma the EQ-5D distinguished between different levels of severity 
although this was not always statistically significant.  Two of three studies in this condition 
showed that it correlated well with other measures but the third study failed to 
demonstrate a relationship. The HUI-3 distinguished between cases and controls in patients 
with glaucoma. The EQ-5D distinguished between people with and without conjunctivitis. In 
the “other” category, the EQ-5D evidence is mixed, but the HUI-3 is supportive.  
While there are 31 studies providing evidence on the validity and responsiveness of EQ-5D, 
HUI3 and SF-6D, overall the evidence base is weak.  Much of the evidence is limited to 
comparisons with general population scores and this is rather crude.  Many of the studies 
had small numbers, so some of the inconsistent findings and lack of statistical significance 
could be due to small numbers.  Furthermore, this often did not control for age or co-
morbidities that may correlate with visual impairment. Finally, there were very few head to 
head studies that really enable a true comparison of performance.  
A new version of the EQ-5D has been developed with the number of levels increased to five 
rather than three. It is possible that this could improve the EQ-5D’s ability to demonstrate 
differences in utility between people with milder severities of visual impairment. Further 
research should be conducted on the validity of the five-level version in people with visual 
impairment.  There is also interest in adding dimensions to EQ-5D to make it more relevant 
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for certain conditions and there is currently a study being undertaken to look at the impact 
of a dimension to pick up the impact of visual impairment on HRQL.  Another solution would 
be to develop a preference-based condition specific index using a widely used Vision specific 
instrument such as the VFQ-25 (Revicki et al., 2008) though there are concerns that 
condition specific preference-based measures may not be comparable across different 
medical conditions (Brazier & Tsuchiya, 2010).  
 
Conclusion 
The review has provided a narrative analysis of preference based measures in visual 
disorders. The broad range of values, and the differing levels of performance in terms of 
construct validity, convergent validity and responsiveness reflects the systematic variance 
attributable to different types of visual disorder, different patient populations and to study 
design.  The number of studies investigating the EQ-5D is much larger than for HUI-3 or SF-
6D. The results of this review show generally consistent results on the validity of the HUI-3 
in people with visual impairment with the exception of diabetic retinopathy, the results for 
EQ-5D were mixed and there was little evidence on the use of the SF-6D. Responsiveness 
was only assessed in the EQ-5D and this was found to be consistent, but not always 
statistically significant. More head to head comparisons are required of these measures 
across visual conditions.  
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Table 1: Characteristics of included studies 
Study reference 
(Author, Year) 
Country  Disease/treatment stage Study type (e.g. cross 
sectional, RCT, cohort) 
GLAUCOMA 
(Aspinall et al., 2008) UK Glaucoma and no other ocular co morbidity Cross-sectional study  
(Kobelt et al., 2006) Sweden Ocular hypertension or open-angle glaucoma Cross-sectional study 
(Mittmann et al., 2001) Canada Glaucoma – a subset from a study on a range of 
chronic conditions 
Cross-sectional study 
(Montemayor et al., 
2001) 
Canada COAG, normal-pressure glaucoma or suspected 
glaucoma with treatment 
Cross-sectional study 
(Thygesen et al., 2008) Multi-country Late-stage primary open-angle glaucoma Case review 
AMD 
(Cruess et al., 2007) Canada NV-AMD Cross-sectional 
observational study 
(Espallargues et al., 
2005) 
UK Wet or dry AMD Cross-sectional study 
(Kim et al., 2010) Korea - Cohort study 
(Lotery et al., 2007) UK Bilateral subfoveal NV-AMD Cross-sectional study 
(Payakachat et al., 2009) Multi-country Wet AMD Cross-sectional study 
(Ruiz-Moreno et al., 
2008) 
Spain Bilateral NV-AMD Prospective case-control 
study 
(Soubrane et al., 2007) Multi-country NV-AMD Cross-sectional study 
CATARACTS 
(Asakawa et al., 2008) Canada +/- other co-morbidities Cross-sectional study 
(Black et al., 2009) UK First or second eye Prospective cohort study 
(Conner-Spady et al., 
2005) 
Canada - Cohort study 
(Datta et al., 2008) UK Bilateral cataracts in over 70s Secondary analysis of RCT 
(Jayamanne et al., 1999) UK First Eye Prospective study 
(Polack et al., 2007) Kenya - Case-control study 
(Polack et al., 2008) Bangladesh - Case-control study 
(Polack et al., 2010) The 
Philippines 
Over 50s Case control study 
DIABETIC RETINOPATHY 
(Lloyd et al., 2008) UK Diabetic Retinopathy due to diabetes Cross-sectional study 
(Smith et al., 2008) US Type-2 diabetes Cross-sectional study 
CONJUNTIVITIS 
(Pitt et al., 2004) UK - Cohort study 
(Rajagopalan et al., 
2005) 
Multi-country Non-Sjogren’s Keratoconjunctivitis or Sjogren’s 
Syndrome 
Cross-sectional study 
(Smith et al., 2005) Spain - Cohort study 
OTHER VISUAL DISORDERS 
(Boulton et al., 2006) UK Vision Impairment or blindness in children Cross-sectional study 
(Clark et al., 2008) Australia Post cataract surgery endophthalmitis Cohort study 
(Kempen et al., 2003) US Cytomegalovirus retinitis in patients with AIDS Prospective cohort study 
(Langelaan et al., 2007) Netherlands Low-vision patients Cross-sectional study 
(Quinn et al., 2004) US Retinopathy of Prematurity Cohort study 
(van Nispen et al., 2009) Netherlands Vision Impairment in older people Observational study 
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Table 2: Instruments used 
Study reference 
(Author, Year) 
Generic Preference 
Based 
Direct 
valuation 
Rating 
scale 
Condition specific HRQoL instruments and 
measures of clinical severity 
EQ-5D SF-6D HUI-3 TTO VAS 
 
VFQ 
(20/25) 
VF 
(14/4D) 
RQLQ VFA IDEEL 
GLAUCOMA 
(Aspinall et al., 2008)           
(Kobelt et al., 2006)           
(Mittmann et al., 2001)           
(Montemayor et al., 2001)           
(Thygesen et al., 2008)           
AMD 
(Cruess et al., 2007)           
(Espallargues et al., 2005)           
(Kim et al., 2010)           
(Lotery et al., 2007)           
(Payakachat et al., 2009)           
(Ruiz-Moreno et al., 2008)           
(Soubrane et al., 2007)           
CATARACTS 
(Asakawa et al., 2008)           
(Black et al., 2009)           
(Conner-Spady et al., 2005)           
(Datta et al., 2008)           
(Jayamanne et al., 1999)           
(Polack et al., 2007)           
(Polack et al., 2008)           
(Polack et al., 2010)           
DIABETIC RETINOPATHY 
(Lloyd et al., 2008)           
(Smith et al., 2008)           
CONJUNCTIVITIS 
(Pitt et al., 2004)           
(Rajagopalan et al., 2005)           
(Smith et al., 2005)           
OTHER VISUAL DISORDERS 
(Boulton et al., 2006)           
(Clark et al., 2008)           
(Kempen et al., 2003)           
(Langelaan et al., 2007)           
(Quinn et al., 2004)           
(van Nispen et al., 2009)           
VFQ20/25 = Visual Function Questionnaire 20/25. VF-14/4D = Visual Functional Questionnaire 14/4 dimension. RQLQ = 
Rhinoconjunctivitis Quality of Life Questionnaire. VFA = Visual Function Assessment. IDEEI = Impact of Dry Eyes on Everyday Life 
questionnaire. 
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Table 3: Utility, Visual Acuity and VAS values 
Study reference  
(Author, Year) 
Instru-
ment 
Index  
(mean (SD)) 
VA  
(logMAR mean (SD) 
unless specified) 
VAS  
(mean (SD)) 
GLAUCOMA 
(Aspinall et al., 
2008) 
EQ-5D 0.76 (0.19) Median group 6/12 or 
better in both eyes 
 
(Kobelt et al., 2006) EQ-5D 0.80 (0.23) (right/left) 0.76/0.74 
(0.30/0.29) 
74.7 (18.2) 
(Mittmann et al., 
2001) 
HUI-3 0.924 (0.086)   
(Montemayor et 
al., 2001) 
EQ-5D 0.89 (range -0.08 to 1.00) -0.10 (0.17)  
(Thygesen et al., 
2008) 
EQ-5D 0.65 (0.28) Best/worst eye 
0.28(0.26) / 0.14(0.18) 
 
AMD 
(Cruess et al., 2007) EQ-5D 0.64 (0.52,0.76) 0.66 (0.64)  
(Espallargues et al., 
2005) 
EQ-5D 0.72 (0.22) Better seeing eye 1.01 
(0.67) 
Worse seeing eye 1.68 
(0.75) 
65.0 
SF-6D 0.66 (0.14) 
HUI-3 0.34 (0.28) 
(Kim et al., 2010) EQ-5D Pre-treatment  0.729 (0.236) 
Post-treatment 0.793 (0.222) 
  
(Lotery et al., 2007) EQ-5D 0.67 0.26 (0.19)  
(Payakachat et al., 
2009) 
EQ-5D 0.7711 (0.21) Median group  for Better 
and worse eye groups: 
20/80 to 20/160  
 
(Ruiz-Moreno et al., 
2008) 
EQ-5D 0.68 (0.62,0.74) 95% CI   
(Soubrane et al., 
2007) 
EQ-5D 0.65 0.6 (0.7)  
CATARACTS 
(Asakawa et al., 
2008) 
HUI-3 -   
(Black et al., 2009) EQ-5D 0.81 (0.23)   
(Conner-Spady et 
al., 2005) 
EQ-5D First eye surgery 0.80 (0.20) 
Second eye surgery 0.78 (0.20) 
First eye, second eye 
VA op 0.58 (0.30), 0.52 
(0.27) 
VA non-op 0.43 (0.28), 
0.29 (0.21) 
First eye surgery 77.5 (17.9) 
Second eye surgery 77.1 
(16.6) 
(Datta et al., 2008) EQ-5D Median 0.73 (0.26) 0.28 [0.16;0.42]  
(Jayamanne et al., 
1999) 
EQ-5D - 90% had VA 6/18-6/60  
(Polack et al., 2007) EQ-5D - Median group <6/60 
>3/60 
 
(Polack et al., 2008) EQ-5D - Median group <3/60 > PL  
(Polack et al., 2010) EQ-5D - Median group <3/60 > PL  
DIABETIC RETINOPATHY 
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(Lloyd et al., 2008) EQ-5D, 
HUI-3 
  
By level of VA: 
No DR - 0.83 (0.20), 0.81 (0.20) 
6/6-6/9 - 0.83 (0.20), 0.78 (0.22) 
6/12-6/18 - 0.50 (0.30), 0.30 (0.38) 
6/24-6/36 - 0.68 (0.29) 
, 0.61 (0.35) 
6/60-6/120 - 0.53 (0.47), 0.52 
(0.50) 
Counting fingers - 0.34 (0.36), 0.37 
(0.00) 
By level of VA: 
No DR - 33% 
6/6-6/9 - 45% 
6/12-6/18 - 9% 
6/24-6/36 - 7% 
6/60-6/120 - 5% 
Counting fingers - 2% 
By level of VA: 
No DR 75.0 (20.6) 
6/6-6/9 - 73.8 (18.1) 
6/12-6/18 - 57.7 (22.7) 
6/24-6/36 - 65.9 (21.1) 
6/60-6/120 - 52.3 (31.3) 
Counting fingers -50.1 (9.0) 
(Smith et al., 2008) EQ-5D 0.8 (0.18) Median group >20/20  
CONJUNCTIVITIS 
(Pitt et al., 2004) EQ-5D -  SAC 81.69 (14.89) 
Control 84.92 (12.54) 
(Rajagopalan et al., 
2005) 
EQ-5D Control 0.87 (0.03) 
Non-SS KCS 0.82 (0.02) 
SS 0.74 (0.03) 
 Control 88.93 (2.06) 
Non-SS KCS 82.45 (1.19) 
SS 66.94 (2.43) 
(Smith et al., 2005) EQ-5D -  SAC 80.09 (15.24) 
Control 83.34 (11.86) 
OTHER VISUAL DISORDERS 
(Boulton et al., 
2006) 
HUI-3 0.34 (0.43)   
(Clark et al., 2008) EQ-5D Cases 0.66 (0.32) 
Controls 0.81 (0.25) 
  
(Kempen et al., 
2003) 
EQ-5D No CMV = 0.71 
Long standing CMV = 0.75 
Newly diagnosed CMV = 0.75 
No CMV =  91 (median) 
Long standing CMV =  88 
Newly diagnosed CMV = 
88 
No CMV = 72.5 
Long standing CMV = 72.2 
Newly diagnosed CMV = 
63.9 
(Langelaan et al., 
2007) 
EQ-5D 0.73 (0.22) Functional Acuity Score 
38.61 (26.5) 
 
(Quinn et al., 2004) HUI-3 All subjects 0.59 (0.39) 
Blind or low vision in better eye 
0.25 (0.37) 
Sighted in better eye 0.78 (0.25) 
No-ROP subjects 0.90 (0.16) 
All subjects - 20/63 
Blind or low vision in 
better eye - Blind 
Sighted in better eye - 
20/40 
No-ROP subjects - 20/20 
 
(van Nispen et al., 
2009) 
EQ-5D Respondents 0.69 (0.24) 
Non-respondents 0.57 (0.29) 
Respondents 0.55 
[0.42;0.77] 
Non-respondents 0.52 
[0.41;0.80] 
 
PL = Perception of light. 
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Table 4: Overall performance by visual disorder 
    EQ-5D HUI-3 SF-6D 
Glaucoma Severity √ √ √ . . 
  Case-control . √ . 
  Correlation √ x √ . . 
  Responsiveness . . . 
AMD Severity √ x x √ √ 
  Case-control √ √ √ √ . . 
  Correlation  x √ √ 
  Responsiveness √ . . 
Cataracts Severity √ √ x x . . 
  Case-control √ √ √ √ . 
  Correlation x √ x . . 
  Responsiveness √√ . . 
Diabetic  Severity x x  x . 
Retinopathy Case-control √ √ √ . 
  Correlation √ . . 
  Responsiveness   . . 
Conjunctivitus Severity . . . 
  Case-control √ √ √ . . 
  Correlation . . . 
  Responsiveness . . . 
Other Severity ? √ √ . 
  Case-control √ √ . . 
  Correlation √ . . 
  Responsiveness . . . 
 KEY 
√ statistically significant 
√ 
trend meeting prior expectation but 
difference not statistically  
significant 
x 
Inconsistent or non-significant 
correlation 
? mixed 
. No evidence 
28 
 
 
Figure 1: Flow diagram showing selection of studies 
 
 
Number of potentially relevant records 
1025 
Number of citations screened 
1025 
Number of citations excluded 
969 
Number of full text articles assessed 
56 
Number of full text articles excluded 
25 
Number of studies included in review 
31 
